Sign in
Taking people in PolandPhase 3

Tests metformin in non-diabetic patients after heart stent procedures for acute coronary syndrome

Tests metformin in adults without diabetes who had a stent for acute coronary syndrome.

Key facts

Who runs it
Wojskowy Instytut Medyczny Panstwowy Instytut Badawczy
Where
Bielsk Podlaski, Bielsko-Biala, Chorzow, Chrzanów, Czestochowa, Dąbrowa Górnicza, Ełk, Gdansk, Gorzów Wlkp, Iława, Kluczbork, Krakow, Kraśnik, Kutno, Legionowo, Mrągowo, Poznan, Pulawy, Racibórz, Sieradz, Sosnowiec, Szczecinek, Tomaszów Mazowiecki, Tychy, Warsaw, and Zgierz, PolandSee the 26 sites
Registry title
"MetCool ACS"- Metformin "Cooling" Effect on metformin-naive Patients Treated with PCI because of Acute Coronary Syndrome
Status
Recruiting
Phase
Phase 3
People taking part
1,000 people, planned
Started
18 Nov 2024
Expected to end
25 Jul 2028
Type of study
Interventional
Record updated
20 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults without diabetes who had a first acute coronary syndrome and were treated with a stent. It tests whether metformin lowers the need for repeat procedures.

Age
Over 18 years
Sex
All sexes
Disease stage
First episode of acute coronary syndrome, treated with percutaneous coronary intervention with a drug-eluting stent, with an uncomplicated course as judged by the treating doctor.
Earlier treatment
No drugs to lower blood sugar before admission or in the last 6 months.
Biomarker or test result
HbA1c below 6,5% (48 mmol/mol) (measured during the hospital stay). No history of diabetes.

Main reasons for not taking part

  • Significant valvular disease on ECHO
  • Pregnancy or breast-feeding
  • Previous CABG (bypass surgery)
  • Chronic kidney disease with GFR below 60 ml/min/1,73 m2
  • Hypersensitivity to metformin

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • Age >18 years
  • First episode of the ACS in accordance with ESC (European Society of Cardiology) treating with percutaneous coronary intervention with drug-eluting stent implantation
  • Profession, place of residence (but close enough that it will not cause difficulty in monitoring during research)
  • Uncomplicated course of the disease (ACS) as assessed by the treating physician
  • Patient negative history of diabetes
  • No hypoglycemic drugs before the admission or in the last 6 months
  • HbA1c< 6,5% (assessment during hospitalization)
  • Written consent to participate in the study

Who cannot take part

  • History of previous CABG
  • Significant valvular disease confirmed in ECHO
  • Known gastro-intestinal disease which could be potentially responsible for metformin intolerance (eg inflammatory bowel disease, GERD- gastro-esophageal reflux disease)- this criterion only for patients from "treatment group"
  • Known potential difficulties in collaboration with patients (dementia, mental disorders, distance from patients residence if considered as potentially problematic, alcoholism)
  • Chronic kidney disease with GFR< 60 ml/min/1,73 m2 modo MDRD
  • ALT three times over UNL (upper normal limit) according to the laboratory criteria
  • Pregnancy and breast - breeding
  • Patient participation in another study
  • NYHA IV during hospitalization
  • Serious co-morbidity and estimated survival time of less than 2.5 years- as assessed by the treating physician
  • Hypersensivity to metformin

Where in Poland

  • Centrum Kardiologii Scanmed w Bielsku PodlaskimBielsk Podlaski, PolandTaking people
  • American Heart of Poland S.A.Bielsko-Biala, PolandTaking people
  • Scanmed S.A.Chorzow, PolandTaking people
  • Małopolskie Centrum Sercowo-Naczyniowe AhoPChrzanów, PolandTaking people
  • Scanmed S.A.Czestochowa, PolandTaking people
  • American Heart of Poland S.A.Dąbrowa Górnicza, PolandTaking people
  • Centrum Kardiologii Scanmed w EłkuEłk, PolandTaking people
  • Uniwersyteckie Centrum KliniczneGdansk, PolandTaking people
  • Wielospecjalistyczny Szpital Wojewódzki w Gorzowie Wlkp. Spółka z Ograniczoną OdpowiedzialnościąGorzów Wlkp, PolandTaking people
  • Centrum Kardiologii Scanmed w IławieIława, PolandTaking people
  • Scanmed S.A.Kluczbork, PolandTaking people
  • Szpital sw. Rafala Scanmed SAKrakow, PolandTaking people
  • 4Cardia Szpital Kardiologii Inwazyjnej z Oddziałem Chirurgii NaczyniowejKraśnik, PolandTaking people
  • Scanmed S.A.Kutno, PolandTaking people
  • Wojskowy Instytut Medyczny - Szpital w LegionowieLegionowo, PolandTaking people
  • NZOZ Pomorskie Centra KardiologiczneMrągowo, PolandTaking people
  • Uniwersytecki Szpital Kliniczny w PoznaniuPoznan, PolandTaking people
  • Samodzielny Publiczny Zaklad Opieki Zdrowotnej W PulawachPulawy, PolandTaking people
  • Centrum Kardiologii Scanmed w RaciborzuRacibórz, PolandTaking people
  • Szpital Wojewódzki im. Prymasa Kardynała Stefana Wyszyńskiego w SieradzuSieradz, PolandTaking people
  • Centrum Kardiologii Scanmed w SosnowcuSosnowiec, PolandTaking people
  • Centrum Kardiologii Scanmed w SzczecinkuSzczecinek, PolandTaking people
  • Centrum Kardiologii Scanmed w Tomaszowie MazowieckimTomaszów Mazowiecki, PolandTaking people
  • American Heart of Poland S.A.Tychy, PolandTaking people
  • Wojskowy Instytut Medyczny Panstwowy Instytut BadawczyWarsaw, PolandTaking people
  • American Heart of Poland S.A.Zgierz, PolandTaking people

About the trial

What the trial wants to find out

The primary objective of the study is to evaluate the effect of metformin in reducing the rate of unplanned coronary revascularization in nondiabetic patients treated with percutaneous coronary angioplasty (PCI) for acute coronary syndrome.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
"MetCool ACS"- Metformin "Cooling" Effect on metformin-naive Patients Treated with PCI because of Acute Coronary Syndrome
Plain-language title
Tests metformin in non-diabetic patients after heart stent procedures for acute coronary syndromeGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
20 July 2026